



Dear Investigators and Study Team,

ACCRU, a cancer research network operating within the Mayo Clinic, has officially partnered with Perthera, a leading precision oncology company, to bring innovative clinical trials to cancer patients throughout the country in the Target Panc Program. Perthera, with its Oncology Operating System™, will serve as the centralized “Molecular CRO” under the umbrella protocol.

Together, Perthera & ACCRU are supporting Target Panc’s new clinical study program aiming to develop hypothesis-generating clinical trials that are highly targeted to pancreatic cancer patients with specific molecular biomarkers. Initially, the program will focus on BRAF mutations and other biomarkers of interest that, in many cases, are present in single digit percentages. We aim to enroll patients from across the nation, whether they have previously had or now require tumor molecular testing, and whose tumor harbors the appropriate biomarker(s).

As the “Molecular CRO”, Perthera’s role is to support you and your patients’ participation in ACCRU’s research program, while accelerating enrollment at established Target Panc sites. Perthera will provide a simple process that works behind the scenes. Once you’ve ordered molecular testing for your patients, nothing else changes in your workflow, and Perthera’s process can seamlessly serve to identify and enroll your patients in the appropriate clinical trials.

For more information, please contact Bre Azad, the Target Panc Educator at Perthera, at (866)-595-6869 or TargetPanc@Perthera.com. We will review the program in more detail and outline the simple steps to deliver this opportunity and its benefits to your patients.

Looking forward to our potential work together.

Best,

Michael (Mike) J. Pishvaian, MD, PhD
Associate Professor, Department of Oncology
Johns Hopkins University School of Medicine
5255 Loughboro Rd NW, Washington, DC 20016
202-660-6500 (Office)
202-660-6501 (Fax)